TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding. Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Limited cross-variant immunity without vaccination (Nature) EUA for boosters in 5-11 year olds (FDA) Stages of COVID-19 (AIDS Rev) B.1.1.529 attack rate in Australia (JID) Scent dogs (BMJ) Does Omicron affect pets? (CVMBS News) Paxlovid eligibility checklist (FDA) Supratherapeutic tacrolimus with nirmatrelvir/ritonavir (Op For Inf Dis) Is longer Paxlovid needed? (Reuters) How about Veklury ? (Gilead) Fluvoxamine declined (FDA) Antigen positivity after isolation (MMWR) Inflammasome activation drives COVID-19 pathology ( TWiV 900 , Nature ) PASC and viral antigen persistence in gut (Gastroenterol) GI symptoms and fecal shedding (Med) Contribute to ASTMH fundraiser at PW Dr. Griffin's treatment guide ( pdf ) Letters read on TWiV 901 Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]